(NASDAQ: MGNX) Macrogenics's forecast annual revenue growth rate of -6.57% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 49.85%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.7%.
Macrogenics's revenue in 2025 is $141,329,000.On average, 4 Wall Street analysts forecast MGNX's revenue for 2025 to be $5,720,260,651, with the lowest MGNX revenue forecast at $1,330,585,098, and the highest MGNX revenue forecast at $9,637,955,075. On average, 2 Wall Street analysts forecast MGNX's revenue for 2026 to be $10,869,060,107, with the lowest MGNX revenue forecast at $7,380,981,485, and the highest MGNX revenue forecast at $14,357,138,730.
In 2027, MGNX is forecast to generate $5,281,857,966 in revenue, with the lowest revenue forecast at $4,387,792,650 and the highest revenue forecast at $6,175,923,283.